Drugs / HST101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06504043 | Sep 2024 → Jan 2025 overdue | hyperlipidemia, low density lipoprotein cholesterol, mild elevation of | Hasten Biopharmaceutical Co., Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HST101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06504043 ↗ |
| Route | Subcutaneous | “HST101 single SC administration of 150 mg or placebo;” NCT06504043 ↗ |